123719-65-3

Usage

Uses

Used in Pharmaceutical Industry:
(+/-)-CIS-3-METHYL-2-PIPERIDINECARBOXYLIC ACID is used as a key building block for the synthesis of various pharmaceutical drugs, particularly for the development of medications targeting central nervous system disorders and inflammation. Its chiral nature allows for the creation of enantiomer-specific drugs, which can have different therapeutic effects and reduce potential side effects.
Used in Organic Synthesis:
(+/-)-CIS-3-METHYL-2-PIPERIDINECARBOXYLIC ACID is used as a precursor for the synthesis of other compounds with biological activity. Its unique structure and functional groups make it a valuable component in the development of new organic compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 123811-72-3 3-methylpicolinic acid hydrochloride 
• 4021-07-2 3-methyl-pyridine-2-carboxylic acid 
• 20970-75-6 2-cyano-3-methylpyridine 
• 1003-73-2 3-picoline-N-oxide 

Downstream Products

• 123834-10-6 (2S,3R)-3-Methyl-piperidine-1,2-dicarboxylic acid 1-tert-butyl ester; compound with dicyclohexyl-amine 

Relevant academic research and scientific papers

The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics

This paper describes our recent efforts to design and synthesise potent and selective PDE5 inhibitors and the use of in vitro predictors of clearance, absorption and permeability to maximise the potential for dose-proportional pharmacokinetics and good oral bioavailability in man. Optimisation of the preclinical profile resulted in the identification of UK-369003 (19a) and its nomination as a clinical candidate. The clinical pharmacokinetic and safety profile has enabled us to progress the compound to test its efficacy in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and a paper describing its efficacy has recently been published.2,3.

PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS

The invention provides compounds of Formula I or Formula II: (I), (II) or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

An Improved Synthesis of Homoproline and Derivatives

An improved, general synthesis of substituted homoprolines has been developed by using readily available substituted pyridines (1).A key step in this synthetic procedure involves the known conversion of pyridine-N-oxides to 2-cyanopyridines (3) in nearly quantitative yields.The resulting nitriles are hydrolyzed to the corresponding pyridine-2-carboxylic acids (4).Subsequent reduction of the aromatic ring with PtO2/H2 gives the homoprolines (5) in good yields as racemic cis isomers.This procedure also can be utilized for the preparation of 5,6-benzohomoprolines fromthe appropriate quinoline precursors.The N-tert-butyloxycarbonyl (Boc) derivatives of these amino acids (useful intermediates for peptide synthesis) were also prepared in good yields.